FDA Clears Philips’ Disposable Patch for COVID-19 Patient Deterioration
The FDA has granted Philips 510(k) clearance for its Philips Biosensor BX100, a patch for use in hospitals to monitor coronavirus patients.
The five-day, single-use wireless patch is designed to assist in the management of confirmed and suspected COVID-19 patients. The wearable patch measures and transmits the top two predictors of deterioration, respiratory rate and heart rate, as well as the patient’s activity level, posture and ambulation.
The patches can be linked with a hub to monitor multiple patients in different hospital rooms.